IDO1 and neoplasm: IDO also catalyzes the conversion of tryptophan to kinurenine, whose level is increased in the tumor microenvironment, where it directly inhibits natural killer cell cytolytic activity through downregulation of activating receptors (NKp44, NKp30, and natural killer group 2D receptor (NKG2D)) [70].